Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics

Genetics in Medicine

Volumn 12, Issue 12, 2010, Pages 801-807

  Julian Reynier, Claire ^a   Bouhnik, Anne Déborah ^a   Mouret Fourme, Emanuelle ^b   Gauthier Villars, Marion ^c   Berthet, Pascaline ^d   Lasset, Christine ^e   Fricker, Jean Pierre ^f   Caron, Olivier ^g   Gesta, Paul ^h   Luporsi, Elisabeth ⁱ   Faivre, Laurence ^j,k   Longy, Michel ^l   Gladieff, Laurence ^m   Frenay, Marc ⁿ   Dreyfus, Héléne ^o   Sobol, Hagay ^p   Vennin, Philippe ^q   Nogués, Catherine ^b  

^a AIX MARSEILLE UNIV   (France)

^b CENTRE RENÉ HUGUENIN   (France)

^c INSTITUT CURIE   (France)

^d CENTRE FRANÇOIS BACLESSE   (France)

^e CENTRE LÉON BÉRARD   (France)

^f CENTRE PAUL STRAUSS   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h CHR Georges Renon   (France)

ⁱ CENTRE ALEXIS VAUTRIN   (France)

^j Medical University of Dijon   (France)

^k CGFL   (France)

^l INSTITUT BERGONIÉ   (France)

^m INSTITUT CLAUDIUS REGAUD   (France)

ⁿ CENTRE ANTOINE LACASSAGNE   (France)

^o INSTITUT SAINTE CATHERINE   (France)

^p INSTITUT PAOLI CALMETTES   (France)

^q CENTRE OSCAR LAMBRET   (France)

more..

Author keywords

BRCA1 2; breast cancer; genetic testing; prophylactic surgery; psychosocial

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; COHORT ANALYSIS; DEPRESSION; FEMALE; FOLLOW UP; FRANCE; GENE MUTATION; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIVARIATE ANALYSIS; PERCEPTION; PROPHYLACTIC SURGERY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RISK REDUCTION; SALPINGOOOPHORECTOMY; SOCIAL ASPECT; TIME;

EID: 78650679238     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181f48d1c     Document Type: Article

References (37)

1. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-1130.
2. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-271.
3. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-689.
4. Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol 2007;14:3335-3344.
5. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:159-164.
6. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004;22:1055-1062. (Pubitemid 41095038)
7. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84.
8. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001;93:1633-1637.
9. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005;23:7491-7496. (Pubitemid 46291812)
10. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorec-tomy for the prevention of BRCA1- and BRCA2-associated breast and gyne-cologic cancer: a multicenter, prospective study. J Clin Oncol 2008;26:1331-1337.
11. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999;91:1475-1479.
12. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-1622.
13. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-1615.
14. Eisinger F, Bressac B, Castaigne D, et al. [Identification and management of hereditary breast-ovarian cancers (2004 update.)] Pathol Biol (Paris) 2006; 54:230-250.
15. Lerman C, Hughes C, Croyle RT, et al. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 2000; 31:75-80.
16. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 2000;355:2015-2020.
17. Lodder LN, Frets PG, Trijsburg RW, et al. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat 2002;73:97-112.
18. Botkin JR, Smith KR, Croyle RT, et al. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 2003;118A:201-209.
19. Schwartz MD, Kaufman E, Peshkin BN, et al. Bilateral prophylactic oopho-rectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol 2003;21:4034-4041.
20. Wainberg S, Husted J. Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol Biomarkers Prev 2004;13:1989-1995.
21. Madalinska JB, van Beurden M, Bleiker EM, et al. Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers. J Clin Oncol 2007;25:301-307.
22. Kram V, Peretz T, Sagi M. Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing. Fam Cancer 2006;5:327-335.
23. Schmeler KM, Sun CC, Bodurka DC, et al. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol 2006;108:515-520.
24. Bradbury AR, Ibe CN, Dignam JJ, et al. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med 2008;10:161-166.
25. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008;122:2017-2022.
26. Beattie MS, Crawford B, Lin F, Vittinghoff E, Ziegler J. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomarkers 2009;13:51-56.
27. Evans DG, Lalloo F, Ashcroft L, et al. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomarkers Prev 2009;18:2318-2324.
28. Skytte AB, Gerdes AM, Andersen MK, et al. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin Genet 2010;77:342-349.
29. Andrieu N, Easton DF, Chang-Claude J, et al. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. J Clin Oncol 2006;24:3361-3366.
30. Fuhrer F. La version française de l'échelle CES-D. Description and translation of the autoevaluation scale [in French]. Psychiatrie et Psychobiologie 1989;4:163-166.
31. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
32. Hann D, Winter K, Jacobsen P. Measurement of depressive symptoms in cancer patients: evaluation of the Center for Epidemiological Studies Depression Scale (CES-D). J Psychosom Res 1999;46:437-443.
33. Horowitz M, Wilner N, Alvarez W. Impact of event scale: a measure of subjective stress. Psychosom Med 1979;41:209-218.
34. Fry A, Rush R, Busby-Earle C, Cull A. Deciding about prophylactic oopho-rectomy: what is important to women at increased risk of ovarian cancer? Prev Med 2001;33:578-585. (Pubitemid 34101881)
35. Stefanek ME, Helzlsouer KJ, Wilcox PM, Houn F. Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med 1995;24:412-419.
36. Frost MH, Schaid DJ, Sellers TA, et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 2000;284:319-324.
37. Julian-Reynier CM, Bouchard LJ, Evans DG, et al. Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer 2001;92:959-968.